Drug Shortage Report for MIDAZOLAM INJECTION
Report ID | 158771 |
Drug Identification Number | 02242905 |
Brand name | MIDAZOLAM INJECTION |
Common or Proper name | Midazolam Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | MIDAZOLAM |
Strength(s) | 5MG |
Dosage form(s) | LIQUID |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 2 mL |
ATC code | N05CD |
ATC description | HYPNOTICS AND SEDATIVES |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2022-04-01 |
Estimated end date | Unknown |
Actual end date | 2022-04-30 |
Shortage status | Resolved |
Updated date | 2022-05-01 |
Company comments | On 100% allocation |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2022-05-01 | English | Compare |
v4 | 2022-04-28 | French | Compare |
v3 | 2022-04-28 | English | Compare |
v2 | 2022-04-13 | French | Compare |
v1 | 2022-04-13 | English | Compare |
Showing 1 to 5 of 5